KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Taxes (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Current Taxes for 8 consecutive years, with $541000.0 as the latest value for Q4 2025.

  • Quarterly Current Taxes rose 207.39% to $541000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $541000.0 through Dec 2025, up 207.39% year-over-year, with the annual reading at $541000.0 for FY2025, 207.39% up from the prior year.
  • Current Taxes hit $541000.0 in Q4 2025 for Adaptive Biotechnologies, up from $176000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $541000.0 in Q4 2025 to a low of $59000.0 in Q4 2023.
  • Historically, Current Taxes has averaged $272200.0 across 5 years, with a median of $194000.0 in 2022.
  • Biggest five-year swings in Current Taxes: tumbled 77.87% in 2021 and later surged 207.39% in 2025.
  • Year by year, Current Taxes stood at $391000.0 in 2021, then plummeted by 50.38% to $194000.0 in 2022, then tumbled by 69.59% to $59000.0 in 2023, then skyrocketed by 198.31% to $176000.0 in 2024, then soared by 207.39% to $541000.0 in 2025.
  • Business Quant data shows Current Taxes for ADPT at $541000.0 in Q4 2025, $176000.0 in Q4 2024, and $59000.0 in Q4 2023.